cefmenoxime and Gonorrhea

cefmenoxime has been researched along with Gonorrhea* in 4 studies

Trials

1 trial(s) available for cefmenoxime and Gonorrhea

ArticleYear
Comparative efficacy of cefmenoxime versus penicillin in the treatment of gonorrhea.
    Antimicrobial agents and chemotherapy, 1983, Volume: 23, Issue:3

    A total of 121 men with complicated infections caused by beta-lactamase-negative Neisseria gonorrhoeae were included in this study. They were randomly assigned to regimens of either cefmenoxime (1.0 g) or procaine penicillin G (4.8 X 10(6) U) intramuscularly. Only the penicillin group also took 1.0 g of probenecid orally. A total of 99 patients completed the study, providing data from 108 infected sites. In the cefmenoxime group, there were 49 urethral, 1 rectal, and 2 pharyngeal infections; in the penicillin group, there were 49 urethral, 4 rectal, and 3 pharyngeal infections. In the cefmenoxime group, all except one urethral infection were eradicated. This patient admitted having had sexual intercourse during the follow-up period and was considered to be reinfected. In the penicillin group, all except one pharyngeal infection were cured. No adverse reactions were noted in either group. In this study, cefmenoxime was as effective as penicillin in the treatment of gonococcal urethritis in men.

    Topics: Anti-Bacterial Agents; Cefmenoxime; Cefotaxime; Gonorrhea; Humans; Male; Penicillins

1983

Other Studies

3 other study(ies) available for cefmenoxime and Gonorrhea

ArticleYear
Corneal perforation secondary to gonococcal keratoconjunctivitis.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2020, Nov-02, Volume: 192, Issue:44

    Topics: Anti-Bacterial Agents; Cefmenoxime; Ceftriaxone; Corneal Perforation; Corneal Transplantation; Drug Therapy, Combination; Erythromycin; Gonorrhea; Humans; Keratoconjunctivitis; Male; Young Adult

2020
[Epidemiological and therapeutic studies on gonorrheal infections--clinical efficacy of T-2588. (Sapporo Clinical Research Group for STD)].
    Hinyokika kiyo. Acta urologica Japonica, 1986, Volume: 32, Issue:10

    T-2588, a new oral cephalosporin antibiotic, for gonorrheal infections, was administered to 146 patients with gonorrheal infection cases (140 urethritis cases in males, 6 cervicitis cases in females). Twenty three strains (20.9%) out of 110 clinically isolated gonococci were PPNG. The MICs of T-2588 for the clinically isolated gonococci strains showed a distribution peak at 0.025 microgram/ml and ranged between 0.0125 microgram/ml to 0.1 microgram/ml when an inoculum size of 10(6)/CFU/ml was used. The distribution of MICs of PPNG also showed a peak at 0.025 microgram/ml and the maximum MIC was 0.2 microgram/ml, which is one dilution tube higher than the maximum MIC of non-PPNG. The rate of complication by Chlamydia trachomatis was 20.9% in male and 33.3% in female. At the dose of 400 mg given 2 times a day, the efficacy rate for the males on the 3rd and 7th day was 90.5% (efficacy rate against PPNG, 73.3%) and 95.3% (80.0%), respectively. At the dose of 300 mg given 3 times a day, it was 93.3% and 100%, respectively, and at the dose of 600 mg given 3 times a day, it was 100% and 100%, respectively. Therefore, the administration of T-2588 3 times a day resulted in a higher efficacy rate than that given 2 times a day. This effect was extremely marked in the case of patients with PPNG. The best clinical results were obtained at a daily dose of 600 mg t.i.d. Although the female patients were few, in number and no conclusion can be drawn, the best results were obtained with a daily dose of 600 mg t.i.d. (100%). There were three mild side effects (1.7%), which could not be attributed to the administration of T-2588 in the present study. In conclusion, T-2588 can be to be expected sufficiently clinically effective against gonorrheal infections, including PPNG, at a daily dose of 600 mg t.i.d. for 3 days.

    Topics: Adolescent; Adult; Age Factors; Cefmenoxime; Cephalosporins; Drug Evaluation; Drug Resistance, Microbial; Female; Gonorrhea; Humans; Male; Middle Aged; Neisseria gonorrhoeae; Sex Factors

1986
Plasma and skin blister fluid levels of cefotiam and cefmenoxime after single intramuscular application of 1 g in gonorrhea.
    Chemotherapy, 1984, Volume: 30, Issue:5

    To predict the clinical efficacy of a new antibiotic in uncomplicated gonorrhea, data pertinent to its pharmacokinetics in man are needed. Before starting clinical trials on cefotiam and cefmenoxime, 1 g of each antibiotic was administered intramuscularly as a single dose to 5 healthy volunteers. Both blood and skin blister fluid samples (obtained by suction and cantharides blistering) were repeatedly taken. Peak plasma levels amounted on average to 24.8 and 48.2 micrograms/ml, respectively. 6 h after dose still average plasma concentrations of 3.4 and 6.52 micrograms/ml were found. Suction blister fluid levels essentially paralleled plasma levels, whereas cantharides blister fluid levels increased and decreased more slowly than plasma levels. Cefotiam penetrated more readily into suction blister fluid than cefmenoxime as obtained from area ratios. Thus, the chosen dosage regimens considered apt for gonorrhea led to high initial as well as long-standing drug levels. And this does not only hold true for the plasma. Facing their good in vitro activity on Neisseria gonorrhoeae, cefotiam and cefmenoxime well deserve further studies in this field including clinical trials.

    Topics: Adult; Blister; Cantharidin; Cefmenoxime; Cefotaxime; Cefotiam; Female; Gonorrhea; Humans; Injections, Intramuscular; Kinetics; Male; Suction

1984